Merck KGaA says it will take some of the billions it made off the sale of its generic business and go after new acquisitions. Executive Director Stefan Oschmann says that one area that the company plans to grow is in vaccines, though he isn't looking for any mega-mergers. He's also interested in biotech companies with late-stage development projects or promising research platforms. The company has a big appetite for deal-making. Merck inked 35 acquisitions and partnerships last year.
- here's the report on Merck from Javno